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Abstract
Background: Resveratrol is known to downregulate the high endogenous level of Heat shock protein 70 (Hsp70) in Chronic
Myelogenous Leukemia (CML) K562 cells and induce apoptosis. Since Heat Shock Factor 1 (HSF1) controls transcription of
Hsp70, we wanted to probe the signaling pathways responsible for transcriptional activation of HSF1.
Methodology/Principal Findings: Cells exposed to 40mM Resveratrol rapidly abolished serine473 phosphorylation of Akt
and significantly reduced its kinase activity. Inactivation of Akt pathway by Resveratrol subsequently blocked serine9
phosphorylation of Gsk3b. Active non-phosphorylated Gsk3b rendered HSF1 transcriptionally inactive and reduced Hsp70
production. Blocking PI3K/Akt activity also demonstrated similar effects on Hsp70 comparable to Resveratrol. Inactivation of
Gsk3b activity by inhibitors SB261763 or LiCl upregulated Hsp70. Resveratrol significantly modulated ERK1/2 activity as
evident from hyper phosphorylation at T302/Y304 residues and simultaneous upregulation in kinase activity. Blocking ERK1/
2 activation resulted in induction of Hsp70. Therefore, increase in ERK1/2 activity by Resveratrol provided another negative
influence on Hsp70 levels through negative regulation of HSF1 activity. 17-allylamino-17-demethoxygeldanamycin (17AAG),
a drug that inhibits Hsp90 chaperone and degrades its client protein Akt concomitantly elevated Hsp70 levels by promoting
nuclear translocation of HSF1 from the cytosol. This effect is predominantly due to inhibition of both Akt and ERK1/2
activation by 17AAG. Simultaneously treating K562 with Resveratrol and 17AAG maintained phosho-ERK1/2 levels close to
untreated controls demonstrating their opposite effects on ERK1/2 pathway. Resveratrol was found not to interfere with
Bcr-Abl activation in K562 cells.
Conclusion/Significance: Thus our study comprehensively illustrates that Resveratrol acts downstream of Bcr-Abl and
inhibits Akt activity but stimulates ERK1/2 activity. This brings down the transcriptional activity of HSF1 and Hsp70
production in K562 cells. Additionally, Resveratrol can be used in combination with chemotherapeutic agents such as
17AAG, an Hsp90 inhibitor reported to induce Hsp70 and hence compromise its chemotherapeutic potential.
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Introduction
Cells are armed with various mechanisms which counteract
stress to maintain cellular homoeostasis when challenged with
subtle to acute changes in the physical, cellular or intracellular
environment. Such a stress response helps the cell to evade
apoptotic cell death and survive. Heat Shock Proteins (Hsps) are a
family of stress proteins, both constitutive and inducible, primarily
with chaperoning properties that help the cell to maintain cellular
protein homeostasis and also to escape apoptosis under diverse
forms of stress, from heat to alkalosis. In normal cells Hsp gene
transcription is under the strict regulation of transcription factors
belonging to the heat shock factor (HSF) family that ensure
prompt switching on of transcriptional activity during stress and
equally important post-stress switch off during recovery [1]. In
cases where this co-ordination of HSF1 activation, stress response
and post recovery deactivation mechanism is not well co-
ordinated, the Hsps become highly overexpressed. This may
render the cells anti-apoptotic and may eventually lead to
malignancy. In fact a large number of malignancies have been
linked to the overexpression of Hsps, in particular Hsp27, Hsp70
and Hsp90 [2].
With the growing evidence of an important role for Hsps in
cancer, researches on chemotherapeutic strategies targeting Heat
shock proteins 90 and 70 have gained momentum over the past
few years [3]. Although the bigger goal remained the same,
research strategies varied ranging from designing targeted small
molecule drugs like 17AAG, against Hsp90 to introduction of
peptide–Hsp70 complexes as anti-cancer vaccines in immuno-
therapy approach [4–6].
Another new approach in treating cancer is the awareness of the
important pharmacological action of many natural products such
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Current research has established important roles for the natural
products in receptor binding, modulation of pro-survival signaling
pathways and targeting various oncoproteins without affecting
normal cells [8]. Epidemiological studies have demonstrated that
the consumption of fruits, soybean and vegetables is related to the
reduction in risk of several types of cancers [9]. Current findings
on Resveratrol suggest that it has role in neuro-protection, cardio-
protection and also has chemopreventive and chemotherapeutic
properties in solid and haematologic malignancies [10–12]. The
uniqueness of Resveratrol lies in its ability to bind multiple targets,
many of which are closely related to the patho-physiological causes
of disease. Resveratrol activates important transcription factors
such as NFkB, STAT3, HIF-1a, b-catenin and antiapoptotic gene
products which include Bcl-2, Bcl-X(L), and inhibitors of apotosis
(IAP such as survivin) [13]. Resveratrol down-regulated Akt,
mitogen-activated protein kinases, and Wnt signaling pathways
[14]. In our previous study we have firmly established that
Resveratrol can target Hsp70 to induce apoptosis in Chronic
Myelogenous Leukemia (CML) [11]. CML cells showed high level
of endogenous Hsp70 both constitutive and inducible which made
the cells resistant to apotosis by the chemotherapeutic drug
Imatinib Mesylate and Nilotinib [15].
Chronic myelogenous leukemia (CML) is associated with a
characteristic chromosomal translocation between chromosomes 9
and 12, called the Philadelphia chromosome. This gene directs the
expression of a mutant, constitutively active tyrosine kinase called
Bcr-Abl that activates a large number of proteins controlling cell
cycle and inhibiting DNA repair, resulting in speeding up of cell
division and incorporation of further genetic abnormalities [16].
Hence the standard care for treating CML is to target Bcr Abl
tyrosine kinase by the pharmacological inhibitors Imatinib or
more potent Dasatinib and Nilotinib [17]. However resistance or
intolerance to these tyrosine kinase inhibitors is often encountered
and therefore warrants the search for alternate targets [18].
Overexpression of the heat-shock protein 70 is associated with
Imatinib resistance in chronic myeloid leukemia [15].We have
previously reported that Resveratrol alters sub cellular localization,
transcriptional activity, and promoter binding of the HSF1 that in
turn downregulates gene expression of hsp70 [11]. However how
Resveratrol modulates HSF1 activity remains unexplored. HSF1
transcriptional activity largely depends on the phosphorylation at
specific residues. Phosphorylation on residues Ser303 and 307 by
GSK3b and p42/44MAPK(ERK) respectively has beenreported to
have a negative regulatory effect on HSF1 activation [19,20].
Recent evidence also claims that negative regulation of HSF1 can
be accomplished by its acetylation at K80 [21]. Therefore, HSF1
seems to be at the crossroads of different signaling pathways and the
heat shock response. Extracellular signal-regulated kinase (ERK) 1/
2 and Akt kinase are reported to be constitutively active in the
chronic phase of CML, blast crisis of CML, and the CML-derived
K562 cell line [22]. MEK1/2 inhibitors sensitize K562 and LAMA
cells to the dual Abl/Src inhibitor BMS-354 825 (Dasatinib)[23]. In
our present study we have tried to decipher the signaling pathways
that contribute to the constitutive activation of HSF1 in K562 cells.
17AAG, an Hsp90 inhibitor is reported to induce Hsp70 [24]
and hence compromise its chemotherapeutic potential. We have
previously shown that Resveratrol can potentiate the antiapoptotic
efficacy of 17AAG in K562 when used in combination [11]. Akt is
a substrate of the chaperone Hsp90. 17AAG downregulated Akt
by virtue of its inhibitory role on Hsp90. Resveratrol is also known
to downregulate Akt activity [25–27]. Even though both
Resveratrol and 17-AAG downregulate Akt activity their effects
on Hsp70 expression are totally dissimilar. Our present study
addresses this contradiction by elucidating the signaling pathways
involving Akt, Gsk3beta and p42/44MAPK. We hereby decipher
a comprehensive signaling pathway to firmly establish the role of
Resveratrol in abrogating the Hsp70 levels in K562 cells.
Materials and Methods
2.1 Materials
Resveratrol was purchased from Calbiochem, UK. Antibodies
against Phospho Akt (ser473, CST) Akt (CST), Hsp72 (Abcam), P-
Gsk3b (Abcam), Erk1/2 (Sigma), P-ERK1/2 (T-202, Y204, CST)
were purchased from established vendors. Monoclonal mouse
anti-actin and mouse anti-Hsp70 antibodies were purchased from
BD Pharmingen. Rabbit anti-HSF1 was obtained from Abcam
and secondary antibodies were obtained from Calbiochem. MBP
and synthetic peptide Gsk3b were obtained from Cayman and
Calbiochem respectively.
2.2 Cell Culture and Drug Treatment Conditions
Human chronic myeloid leukemia cells K562 obtained from the
Cell Repository of National Centre for Cell Science, Pune, India
were maintained in exponential growth in RPMI-1640 medium
supplemented with 10% heat-inactivated fetal bovine serum, 100
units/mL penicillin and 100 mg/mL streptomycin in a humidified
atmosphere of 5% CO2 at 37uC. Resveratrol, Wortmanin,
17AAG, SB216763, U0126 or LiCl were dissolved in dimethyl-
sulfoxide or water (only for LiCl) at a concentration of 40mM,
1mM, 2.5mM, 5mM, 10mM and 1M respectively and added to
cells at the indicated concentrations and time.
2.3 Western Blot
Protein-extracts, 20–50 mg, were first separated by 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
were then transferred onto polyvinylidene fluoride membrane. After
blocking with 5% bovine serum albumin (BSA), membranes were
incubated overnight at 4uC with respective primary antibodies. The
membranes were incubated with 1:5,000 dilutions of the appropriate
peroxidase-conjugated secondary antibodies and or alkaline phos-
phatase-conjugated antibodies and developed for detection by
chemiluminescence or colorimetry. Western blots were scanned
and the bands were quantified by using NIH ImageJ software.
2.4 Immunoprecipitation and Radioactive Kinase Assay
Equilibration of bead with IP buffer: 40ml–60ml of 1:1 protein
agarose A was taken and centrifuged at 10000g for 1 min and the
supernatant was aspirated. The beads were suspended in IP buffer
and centrifuged at 1000g for 1 min. After equilibration with IP
buffer beads were washed and suspended in 50mL IP buffer. 1mgo f
required antibody was added (ERK1/2 or Akt) to 1mg of treated
and untreated lysate and incubated overnight at 4uC in spin wheel.
The equilibrated beads were added to the protein/antibody
homogenate on the next day and incubated at 4uC for 2 K hi na
spin wheel. The beads were collected by centrifugation, washed
and suspended in 15 mL IP buffer to be used for radioactive or
nonradioactive kinase assay. Radioactive assay for Erk1/2 was
performed using 10 mg of MBP with 9 ml of final immunoprecip-
itate bead in 15 ml reaction mix respectively containing 50 mM
Tris–Cl pH 8.0, 10 mM MgCl2,5 0mM ATP and 5 mCi of [c-
32P]
ATP (3000 Ci/mmol). The reactions were carried out for 15 min
at 25uC after which they were stopped by adding 46 sample
loading buffer. The samples were subjected to SDS-PAGE, the
gels were dried and exposed at 280uC as required on an X-ray
film and developed. Non radioactive assay for Akt used similar
protocol with only the radioactive ATP being replaced by 200mM
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reaction, normal Western blot analysis was performed with P-
Gsk3b (serine9) primary antibody. The films were scanned and
quantified using Image J software.
2.5 Fluoroscence Microscopy
K562cellswerefixedin4%p-formaldehydeinphosphatebuffered
saline(PBS) and incubated at room temperature for 30 min. The cells
were washed twice with chilled PBS (washed at 6000g for 5 min. at
4uC). The cells were permeabilized with 0.2% Triton6100 for
10 min at 37uC, followed by blocking with 3% BSA in PBS for 2h at
room temperature. The cells were incubated with desired antibody
solution (Phospho Erk1/2 or Phospho Akt) in PBS with 1% BSA
overnight and then incubation with secondary antibody conjugated
with FITC was done for 1h at room temperature. The cells were
washed in PBS several times and then loaded on slide with 10uL of
DAPI (Vecta Shield procured from Vector Laboratory Inc USA).
Coverslips were sealed of with nail-polish and viewed at 406
magnification using 535nm emission wavelength for FITC and
445nm for DAPI in Zeiss fluorescence microscope.
2.6 Statistical Analysis
Student’s t-test was used to calculate statistical significance of
the data.
Results
3.1 Resveratrol Downregulates the Akt/PKB
Phosphorylation and Activity
We first confirmed if Resveratrol has any significant role in
altering the Akt activity. 40mM Resveratrol significantly curtailed
the phosphorylation (Ser 473) of Akt by .25% within 1h of
treatment of K562 cells (Fig. 1A). This effect was further bolstered
at later time points up to 9h with a significant drop of around 10
fold (P,0.05) registered at 6h (Fig 1B). Phosphorylation of Akt at
473 serine residue is directly linked to the kinase activity of the
protein. Therefore a kinase assay was performed to determine if
Resveratrol could also efficiently alter the catalytic activity of Akt.
Exposure to 40mM Resveratrol for 6 h resulted in a significant
drop (84%67%) in the kinase activity of Akt (Fig. 1C). Resveratrol
thus effectively compromised the phosphorylation and activity of
one of the major oncoprotein, Akt, highly active in chronic
myelogenous leukemia. Fig. 1D demonstrates that phosphorylated
Akt is predominantly located in the nucleus of K562 cells but in
K562 cells treated with Resveratrol for 6h phosphorylated Akt
could be visualized neither in the nucleus nor in other parts of the
cell. Akt in both cases (untreated control and Resveratrol treated)
is almost equally distributed in the cytoplasm and nucleus (Fig. S1).
Fig. 1E shows the phosphorylation status of the Akt substrate
GSK-3b (serine9) which is markedly phosphorylated in K562 cells
Figure 1. Alteration in Akt activation in response to Resveratrol: (A) Akt phosphorylation shown in immunoblot. In the upper panel
phospho serine
473 Akt immunoblot is displayed. In the middle panel Akt and in the lower panel Actin immunoblots are displayed to indicate loading
controls. K-Ctrl – untreated K562 cells; K+ R1H- K562 cells treated with Resveratrol for 1h; K+ R3H- K562 cells treated with Resveratrol for 3h; K+ R6H-
K562 cells treated with Resveratrol for 6h; K+ R9H- K562 cells treated with Resveratrol for 9h. (B) The panel displays the ratio (mean6SD) of the
P-Akt protein/Akt protein band densities of K562 control cells (K-Ctrl) and 6h Resveratrol treated cells (K+ R6H) from three
experiments. (C) Results of Akt Kinase assay are displayed as immunoblot. Total Akt was immunoprecipitated from Resveratrol treated or
untreated cell lysates (containing equal amount of total protein) and kinase assay was performed with equal amount of the precipitated beads and
GSK3b synthetic peptide and ATP as substrates and P- GSK3b was detected by Western Blot using anti serine
9 GSK3b antibody. K-Ctrl – untreated
K562 cells; K+ Res (6H) - K562 cells treated with Resveratrol for 6 h. (D) Cellular localization of phospho serine
473 Akt by fluorescence
microscopy. A: Untreated K562 cells (K-Ctrl) processed for visualization of P-Akt with secondary antibody FITC conjugate.; B: Untreated K562 cells
processed for visualization of DNA using specific stain DAPI; C-: DIC images of the cells; D: K562 cells treated with Resveratrol for 6 h and processed
for visualization of P-Akt with secondary antibody FITC conjugate.; .E: K562 cells treated with Resveratrol for 6 h and processed for visualization of
DNA using specific stain DAPI; F: DIC images of the cells. (E) Phospho-GSK3 immunoblot. Upper panel shows phospho-GSK3b and lower panel
shows actin as loading control. K-Ctrl – untreated K562 cells; K+ R12H - K562 cells treated with Resveratrol for 12h; K+ R24H - K562 cells treated with
Resveratrol for 24h. The bar represents 10mm. All the blots and micrographs are representative of two to three sets of separate experiments.
Concentration of Resveratrol is 40mM. Details of the experiments are described in section-2.
doi:10.1371/journal.pone.0008719.g001
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3.2 Effects of Blocking Akt Activation Pathway by PI3-
Kinase Inhibitor Wortmanin
In our previous study we have conclusively established that
Resveratrol downregulated Hsp70 levels and induced apoptosis in
K562 cells [11]. However it was not exactly known how Resveratrol
accomplished this effect on Hsp70. Exposure to Wortmanin
(0.5 mMa n d1 mM), a potent pharmacological inhibitor for PI3K,
heavily curtailed the phosphorylation of (serine 473)Akt and
(serine9)Gsk3b(Fig. 2A) in K562 cells. Hsp70 levels and stress
inducible form Hsp72 showed subsequent drop in protein levels on
exposure to Wortmanin (Fig 2A). Since Resveratrol blocked Akt
activation it was essential to demonstrate if Akt activation pathway
was involved in modulating the subcellular distribution and
activation of HSF1, the transcription factor responsible for
expression of hsp70 gene. Measuring the levels of cytosolic and
nuclear fraction of HSF1 by Western blot analysis, it was found that
exposure to 0.5mM Wortmanin for 24h appreciably augmented the
cytosolic localization of HSF1 which showed a further increase at
1mM concentration. In contrast Wortmanin at both the above
concentrationsclearlydecreasedthelevelsofnuclearHSF1(Fig2B).
Wortmanin treatment also lowered the phosphorylated form of
Gsk3b levels, which is the catalytically inactive form. This is quite
understandable as Gsk3b is a substrate for phosphorylation by Akt.
Therefore it was interesting to see if Gsk3b inactivation could result
in upregulation of Hsp70 in K562 cells. Blocking Gsk3b by two
different inhibitors LiCl (10mM) and SB216763 (5 mM) resulted in
considerable increase in Hsp72 levels over untreated control after
24h of treatment (Fig 2C). LiCl exerted a stronger increase of 2.5
fold whereas SB216763 produced a moderate increase of 1.7 fold.
3.3 Upregulation of ERK1/2 Activity by Resveratrol
Resveratrol at 40 mM concentration was found to induce
hyperphosphorylation of ERK1/2 in a time dependent manner
(Fig 3A). The induction of Phosphorylation of ERK1/2 was most
prominent at 12h which recorded almost 3.2 fold increase over
control when normalized to internall o a d i n gc o n t r o la c t i n( F i g .3 B ) .
Hsp72 (stress induced Hsp70) also showed a simultaneous decline on
Resveratrol exposure up to 24h (Fig 3A). However the decline in
Hsp72 status was most prominent at 12 and 24h (drop of ,40%) with
almost no appreciable change taking place up to 6h. Resveratrol was
shown to induce ERK1/2 phosphorylation in a time dependent
manner. Whether this hyper-phosphorylated status of ERK1/2 also
reflected in the kinase activity of the protein was important to
understand. In vitro radioactive kinase assay was performed using
radiolabelled ATP and MBP as substrates of the ERK1/2 protein
immunoprecipitated from the whole cell extracts either exposed to
40mM resveratrol for 18h or left untreated. High level of radiolabelled
MBP (P-MBP) was detected by autoradiography for cells treated with
Resveratrol (Fig 3C) compared to that of untreated control.
Resveratrol brought about almost a 2.4 fold increment in kinase
activity. When cells were treated with P-ERK1/2 antibody and
visualized by FITC conjugated secondary antibody, Resveratrol was
found to induce ERK1/2 phosphorylation as K562 cells treated with
Resveratrol showed distinct green florescence compared to untreated
control (Fig. 3D). P-ERK1/2 was found to be distributed more
abundantly in the nucleus. Resveratrol was found to simultaneously
induce ERK1/2 phosphorylation and downregulate Hsp72 levels in
K562 cells. However it was important to understand if there was any
correlation between these two events. Therefore ERK1/2 activity
was blocked using the pharmacological inhibitor against MEK,
U0126. Blocking activation of ERK1/2 by growing cells in presence
of inhibitor for 24h resulted in simultaneous up-regulation in the
Hsp72 levels by almost 1.8 fold (Fig 3E).
3.4 17AAG Treatments Blocks Akt but Boosts the Hsp 70
Levels
The findings above indicated the important roles of Akt and
ERK1/2 activation in down regulation of Hsp70. However the
question that needs to be addressed is how diminishing Akt activation
Figure 2. Effects of Wortmanin, SB216763 and LiCl treatment on K562 cells: (A) Uppermost panel depicts the protein level of Hsp70
by Western blot. Second panel from top depicts Hsp72 by Western blot. The third panel from top shows phosho serine
9 GSK3b by Western blot.
The fourth panel from top shows phospho serine
473 Akt levels by Western blot. The fifth and the sixth panels from top displays Akt and actin protein
levels by Western blot to denote loading controls. K-Ctrl - control K562 cells; K+0.5W- K562 cells treated with 0.5mM Wortmanin for 24h; K+1W- K562
cells treated with 1mM Wortmanin for 24h. (B) Localization of HSF1 after Wortmanin exposure. Uppermost panel represents cytosolic
localization of HSF1 after 24h treatment with different concentrations of Wortmanin. The second panel from top represents actin immunoblots to
indicate loading control for cytosolic fraction. The third panel from top represents nuclear localization of HSF1 after 24h treatment with different
concentration of Wortmanin. The fourth panel from top represents Histone2B immunoblots to indicate loading control for nuclear fraction. K-Ctrl -
control K562 cells; K+0.5W- K562 cells treated with 0.5mM Wortmanin; K+1W- K562 cells treated with 1mM Wortmanin. (C) Effect of GSK3b
inhibitors on Hsp72 levels. Upper panel represents immunoblot of Hsp72 and lower panel represents actin immunoblot to indicate loading
control. K-ctrl - K562 cells left untreated; K+ SB – K562 cells treated with GSK pharmacological inhibitor 5 mM SB216763 for 24h; K+ LiCl - K562 cells
treated with 10mM LiCl for 24 h. All blots are representative of two separate experimental sets.
doi:10.1371/journal.pone.0008719.g002
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of stress response by sharply augmenting the Hsp70 levels (Fig 4A).
17AAG blocks the chaperoning activity of Hsp90, prompting
degradation of its client protein Akt. This is well demonstrated by
the dose dependent decline of Akt and phospho serine 473 Akt levels
in K562 cells treated with 2.5mMa n d5mM concentration of 17AAG
(Fig 4A). Phospho Gsk3b levels also showed a sharp decline with
treatment with 2.5 mM 17AAG and this de-phosphorylation of Gsk3b
was further augmented at higher concentration of 5 mM 17AAG
(Fig 4B). Since down regulation of Akt activity and corresponding
Gsk3b activation both are known to be associated with Hsp70 down
regulation (Fig 1,2) the effect of 17AAG on ERK1/2 gains importance
and holds the key to this apparent puzzle. Exposure to 17AAG
induced a distinct de-phosphorylation of ERK1/2 (T-202/Y-204) by
several fold (8 fold, P,0.05). When combined with Resveratrol,
17AAG demonstrated an opposite effect on ERK1/2 activation in
K562 cells. After simultaneous exposure of K562 to both 40 mM
Resveratrol and 2.5 mM 17AAG for 24h the levels of P-ERK1/2 were
much higher than that in cells treated with 17-AAG alone and were
close to untreated controls (Fig 4C). In comparison, ERK1/2
Phosphorylation status in response to only 40 mM Resveratrol
recorded almost 2 fold increase over control (Fig 4C).
3.5 Resveratrol Does Not Inhibit Tyrosine Kinase Bcr-Abl
in K562
Most of the current drugs for Philadelphia chromosome
+ CML
patients undergoing clinical trials are effectively Tyrosine Kinase
inhibitors blocking Bcr-Abl activity. Resveratrol acted downstream
of Bcr-Abl as evident from Western blot analysis of Phospho Bcr-
Abl. K562 cells exposed to 40mM Resveratrol for various time
intervals ranging from 30min up to 12h failed to demonstrate any
significant alteration of Bcr-Abl phosphorylation status (Fig 5).
Discussion
Over the last few years Resveratrol have been the subject of
extensive research which has elucidated the multifaceted role of
this phytochemical from chemotherapeutic/chemopreventive
potential to promoter of longevity [28]. The list of molecules
targeted by Resveratrol is long and is being continuously updated.
Figure 3. Alteration in p42/44 ERK activation in response to Resveratrol: (A) Effect of Resveratrol on ERK phosphorylation. In the
upper panel phospho threonine
202/phospho tyrosine
204 p42/44 ERK immunoblot is displayed. In the middle panel Hsp72 immunoblot is displayed
and in the lower panels Actin immunoblot and ERK1/2 immunoblots are displayed to indicate loading controls. At the top of the upper and middle
panels band densities of P-ERK and Hsp70 bands are given as percentage of control values taken as 100. K-Ctrl – untreated K562 cells; K+ R6H- K562
cells treated with Resveratrol for 6 h; K+ R12H- K562 cells treated with Resveratrol for 12 h; K+ R24H- K562 cells treated with Resveratrol for 24 h; (B)
The figure displays the ratio (mean6SD) of the P-ERK1/2 protein/actin protein band densities of K562 control cells (K-Ctrl) and 12h
Resveratrol treated cells (K+ R12H) from three experiments. (C) ERK1/2 Kinase Assay. Results of ERK1/2 Kinase assay is displayed as
autoradiograph. Total p42/44 ERK was immunoprecipitated (IP) from Resveratrol treated or untreated cell lysates (containing equal amount of total
protein) and kinase assay was performed with equal amount of the precipitated beads and purified MBP and radioactive ATP as substrates. The
figures above the panel represents band intensity as percentage of control values taken as 100. Blank: Kinase assay buffer without the IP beads; K-Ctrl
– untreated K562 cells; K+ Res (18H) - K562 cells treated with Resveratrol for 18h. The lower panel depicts coomassie stained bands to denote equal
amount of MBP used for the kinase reaction. (D) Cellular localization of phospho threonine
202/phospho tyrosine
204 p42/44 ERK by
fluorescence microscopy. A: Untreated K562 cells (K-Ctrl) processed for visualization of P-ERK with secondary antibody FITC conjugate.; B:
Untreated K562 cells processed for visualization of DNA using specific stain DAPI; C-: DIC images of the cells; D: K562 cells treated with Resveratrol for
18 h and processed for visualization of P-ERK with secondary antibody FITC conjugate.; E : K562 cells treated with Resveratrol for 18h and processed
for visualization of DNA using specific stain DAPI; F: DIC images of the cells. The bar represents 10mm. (E) Effect of ERK inhibitor on Hsp72 levels.
Upper panel depicts Hsp72 and the lower panel shows actin immunoblots to represent protein loading. K-ctrl - K562 control cells; K+ 10U (24H) -
K562 cells treated with pharmacological inhibitor against MEK, U0126 (10 mM) for 24h. All the blots and micrographs are representative of two to
three sets of separate experiments. Concentration of Resveratrol is 40mM. Details of the experiments are described in section-2.
doi:10.1371/journal.pone.0008719.g003
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targets are often not well studied. We have previously established
the efficacy of Resveratrol as a pro-apoptotic agent in K562 cells,
essentially by virtue of its effect on the cellular chaperone Hsp70
[11]. As high endogenous levels of Hsp70 is a pathophysiological
feature not only of CML but also of a large number of cancers
[29], the downregulation of Hsp70 by Resveratrol in K562 serves
as a very effective indicator of the chemotherapeutic potential of
Resveratrol. This makes understanding of the signaling pathways
modulated by Resveratrol for downregulating Hsp70 more
relevant. Resveratrol has been shown to be able to induce
apoptosis in Imatinib mesylate-resistant human chronic myelog-
enous leukemia cell lines [30]. Exaggerated expression of Hsp70 is
reported to be the most important protein responsible for Imatinib
resistance in CML [15,30]. There are some reports on the effect of
Resveratrol on Akt and MAPK pathways, but the connections
between these signaling pathways and Hsp70 have not been
thoroughly explored. Resveratrol was found to modulate the
function of HSF1 as a transcription factor for Hsp70 in K562 cells
[11]. However the role of upstream kinases in controlling HSF1
activity was not properly delved into.
PI3K/Akt pathway has emerged as one of the essential signaling
mechanisms in ABL leukemogenesis as its downstream effectors
are responsible for propagating the signals to promote myeloid and
lymphoid transformation [31]. Resveratrol was able to diminish
the levels of the activated form of Akt phosphorylated at ser437
within 3h of incubation and this effect was even more pronounced
at 6h. Akt activity was also suppressed as supported by the in vitro
Akt substrate phosphorylation experiment (Fig. 1C). The Akt
pathway has been the target of many natural compounds like
Resveratrol, Curcumin, tea polyphenols etc. for exerting their
chemopreventive effects [8]. Phosphorylated Akt is responsible in
activating and de-activating phosphorylation of numerous sub-
strates. Blocking of Akt phosphorylation by the PI3K inhibitor
Wortmanin indicated that Hsp70 expression is dependent on
activated Akt. (Fig, 2A). The phosphorylation based inactivation of
GSK3b (ser9) by Akt is also abrogated in presence of Wortmanin
(Fig 2A). It is reasonable to assume that GSK3b is more active in
the absence of its inhibitory phosphorylation at ser9. Also, the
HSF1 translocation to the nucleus was abrogated by Wortmanin
at concentration as low as 0.5mM. Thus Akt pathway controls the
translocation of HSF1 to the nucleus. The HSF1 activation and
translocation to the nucleus is dependent on phosphorylation of its
multiple amino acid residues [32]. One of these phosphorylation is
contributed by GSK3b at ser 303 that prevents HSF1 to
accumulate in the nucleus [33]. Thus the activation of GSK3b
in presence of Resveratrol definitely contributes to the blocking of
HSF1 translocation to the nucleus and hence Hsp70 expression.
We also provided evidence of involvement of GSK3b in the
upregulation of Hsp70 by using LiCl, known to be a classical
inhibitor of GSK3b and the synthetic specific inhibitor SB216763.
In presence of LiCl and SB 216763, K562 cells exhibited higher
induction of Hsp70 indicating the process to be governed by
GSK3b. Although LiCL is a powerful inhibitor of GSK3b it also
inhibits other protein kinases and influences inositol phosphate
signaling [34]. Furthermore, LiCl has been shown to stimulate Akt
which phosphorylates and inhibits GSK3b [34]. Therefore, LiCl
may inhibit GSK3b in different ways and emerge as a less specific
but more potent inhibitor of Hsp70 expression possibly through its
action on other cellular targets. In contrast, SB216763 is a very
specific inhibitor of GSK3b and does not inhibit other protein
kinases [34]. As a result, SB216763 may act through a single target
and have a more moderate effect on Hsp72 levels.
We also checked the effect of Resveratrol on phospho ERK1/2
as this kinase is required for the primary priming of HSF1 at ser
307 so that GSK3b can perform the secondary phosphorylation
on HSF1 at ser 303 resulting in a cytoplasmic –inactive form of
HSF1 [33]. In presence of Resveratrol there was a considerable
increase in the phosphorylated ERK1/2 signal and ERK1/2
activity was also enhanced (Fig 3A–C). The command of phospho
ERK1/2 on the suppression of Hsp70 expression in K562 cells
was shown by inhibiting ERK1/2 kinase activity with U0126
which resulted in an elevated expression of Hsp72 (Fig. 3E). From
Figure 4. Effects of 17AAG and Resveratrol treatment on K562
cells: (A) Effects of 17-AAG on phosphorylations of Akt and
ERK 1/2, and protein levels of Hsp70. Uppermost panel depicts
phospho serine
473 Akt levels by Western blot. Second panel from top
depicts Akt by Western blot to represent protein loading. The third
panel from top indicates phospho threonine
202/phospho tyrosine
204
p42/44 MAPK immunoblot. The fourth panel from top shows p42/44
MAPK by Western blot to represent corresponding loading control. The
fifth panel from top displays Hsp70 protein levels and sixth panel
depicts actin protein levels by Western blot. K-Ctrl - control K562 cells;
K+2.5G- K562 cells treated with 2.5mM 17AAG for 24h; K+5G- K562 cells
treated with 5mM 17AAG for 24h. (B) Effect of 17-AAG on GSK3b.
The upper panel shows immunoblots of phospho serine
9 GSK3b in
response to treatment with different dose concentration of 17AAG for
24h. The lower panel represents actin immunoblots. K-Ctrl - control
K562 cells; K+2.5G- K562 cells treated with 2.5mM 17AAG for 24h; K+5G-
K562 cells treated with 5mM 17AAG for 24h. (C) Effects of a
combination of 17-AAG and Resveratrol on phosphorylation
status of ERK1/2. The top panel indicates phospho threonine
202/
phospho tyrosine
204 p42/44 ERK immunoblot and the bottom panel
indicates p42/44 ERK to represent protein loading.. K-Ctrl - untreated
K562 cells; K+ 40Res - K562 cells treated with 40mM Resveratrol for 24h;
K+2.5G- K562 cells treated with 2.5mM 17AAG for 24h; K+2.5G+40Res -
K562 cells treated simultaneously with 2.5mM 17AAG and 40mM
Resveratrol for 24h. All blots are representative of two to three
independent experimental sets.
doi:10.1371/journal.pone.0008719.g004
Figure 5. Effects of Resveratrol treatment on phosphorylation
of Bcr-Abl. Upper panel depicts phospho tyrosine
177 Bcr-Abl
immunoblots at various time points after 40mM Resveratrol treatment
in K562 cells. Lower panel represents c-Abl protein levels by Western
blot to indicate protein loading. K-Ctrl - untreated K562 cells; K+0.5H
Res – K562 cells treated for 30min with Resveratrol; K+3H Res – K562
cells treated for 3h with Resveratrol; K+6H Res – K562 cells treated for
6h with Resveratrol; K+12H Res – K562 cells treated for 12h with
Resveratrol.
doi:10.1371/journal.pone.0008719.g005
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influences the two kinases namely GSK3b and ERK1/2 (Fig. 6).
These in turn inactivate HSF1 so as to decrease Hsp70
expression in K562 cells in presence of Resveratrol.
The exact mode of action of Resveratrol in connection with
inhibition of Akt and stimulation of ERK activity is not apparent
at present. However, the literature shows that Resveratrol-induced
ERK activation may happen through induction of sirtuin SIRT1
(silent mating type information regulation 2 homolog) by
Resveratrol [35]. However, Akt inhibition may take place in a
SIRT1 –independent way [35,36] through disruption of interac-
tion between upstream signaling elements such as PI3 Kinase or
Grb2 (growth factor receptor-bound protein 2) with further
upstream proteins relaying signals directly from the receptor [36].
While proposing the role of Akt in downregulating Hsp70 by
Resveratrol in K562 cells we contradicted the observation of
induction of stress response by 17AAG, a drug that is also known
to lower Akt levels (Fig. 4A) by virtue of its action on Hsp90.
17AAG was found to reduce ser473 phosphorylation of Akt and
ser9 phosphorylation of Gsk3b (Fig. 4A and B) exhibiting virtually
similar effects as of Resveratrol on Akt and Gsk3b. But 17 AAG
effect on Hsp70 strikingly differed with Resveratrol in the
Resveratrol mediated downregulation of Hsp70 as 17 AAG
exposure resulted in the upregulation of Hsp70. (Fig 4A). To
explain this paradox we looked at the effect of 17AAG on ERK1/
2 activation we found that ERK1/2 was markedly dephosphor-
ylated when cells were exposed to 2.5mM and 5mM 17AAG
(Fig. 4A). As ERK1/2 plays an extremely important role in
negatively influencing HSF1 activity through a priming phos-
phorylation [33], ERK1/2 inactivation by 17AAG seems to
positively influence Hsp70 transcription by making the available
pool of HSF1 active. Moreover it seems likely that in absence of
the priming phosphorylation of HSF1 by ERK1/2, the secondary
effect of the activated Gsk3b failed to inhibit HSF1 activity. This
not only answers the initial apparent contradiction but further
illustrates the essential involvement of both the Akt and ERK1/2
pathways in lowering of the Hsp70 levels by Resveratrol (Fig. 6).
17AAG is known to downregulate Bcr-Abl activity, however our
study (Fig 5) along with a previous report [30] indicate that
Resveratrol acts downstream of Bcr-Abl activity. This makes it
tempting to propose that Resveratrol when used in combination
may potentiate the action of the presently marketed Bcr-Abl
inhibitors such as Imatinib mesylate,.
In essence, this present study provides a comprehensive
investigation on the effect of Akt inactivation, Gsk3b activation
and upregulation of ERK1/2 activity by Resveratrol in modulat-
ing the transcriptional efficacy of HSF1 and subsequent lowering
of the Hsp70 levels in K562 cells.
Supporting Information
Figure S1 Localization of Akt in untreated control K562 and
Resveratrol-treated (6h) K562 cells.
Found at: doi:10.1371/journal.pone.0008719.s001 (1.35 MB TIF)
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Figure 6. Schematic representation of the signaling pathways operative in Hsp70 regulation in Chronic Myelogenous Leukemia. Akt
and ERK1/2 both phosphorylate HSF1 on serines (ERK1/2 on serine 307 and GSK3b on serine 303 to negatively influence HSF1 activity). In fact, the
phosphorylation by ERK1/2 at Serine 307 is the priming event and it facilitates the phosphorylation by GSK3b at serine 303 which has vital regulatory
influence on HSF1 activity. Resveratrol inhibits Akt but stimulates the activity of ERK1/2. Therefore, Resveratrol is able to influence both the priming
and the subsequent inhibitory phosphorylation. 17-AAG inhibits Akt and as a consequence decreases the phosphorylation of GSK3b and makes
GSK3b active. However, 17AAG also decreases the activation of ERK1/2. Therefore, the active GSK3b is not able to negatively influence HSF1 activity.
17-AAG binds Hsp90 and releases Hsp90 bound HSF1. Free HSF1 in the absence of negative influence of phosphorylations enters the nucleus and
triggers the transcription of Hsp70.
doi:10.1371/journal.pone.0008719.g006
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